Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on November 4, 2013, covering events occurring on October 29, 2013. The filing addresses significant changes in corporate governance and executive leadership.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed relates to executive compensation:
- Severance Payment: Approximately $318,000 in severance and customary benefits for the departing Chief Operating Officer, subject to conditions including the signing of a general release of claims.
Material Changes
The report details the following material changes in personnel and agreements:
- Board Election: Jeffrey A. Duchemin, the Company's Chief Executive Officer, was elected to the Board of Directors effective October 29, 2013, filling a vacancy.
- Executive Appointment: Mr. Duchemin was appointed as President of the Company.
- Departure of Officer: Susan M. Luscinski resigned as Chief Operating Officer (COO). The COO position is being eliminated effective November 30, 2013.
- Role Consolidation: Mr. Duchemin will assume the responsibilities previously held by the COO.
- Agreement Termination: The amended and restated employment agreement with Ms. Luscinski was terminated effective November 30, 2013.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. The primary risk disclosed is the transition of executive responsibilities and the associated severance liability.
Investor Verification Checklist
- Verify the terms of the Employment Agreement between the Company and Jeffrey A. Duchemin (filed August 29, 2013) to understand the basis for his Board election and President appointment.
- Review the definitive Proxy Statement filed April 12, 2013, for details on the terminated employment agreement with Susan M. Luscinski.
- Confirm the conditions precedent for the $318,000 severance payment, specifically the requirement for Ms. Luscinski to sign a general release of claims.
- Monitor the operational impact of consolidating the CEO, President, and former COO roles under one individual.